Skip to content
Regeneron
-
Regeneron expands oncology partnership with CytomX to US$4B for next-generation cancer biologics
Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.
-
Regeneron strikes US$2.32B partnership with Parabilis to advance next-generation peptide therapies
Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.
-
Telix signs USD4.3 billion partnership with Regeneron to expand next-generation precision oncology
The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.
-
Regeneron partners with Tessera Therapeutics in USD275M deal to develop gene writing therapy for AATD
Regeneron is investing USD 150 million in equity and upfront payments to acquire half of the global development and commercialization rights for TSRA-196.